Association between metabolic syndrome and progression in Parkinson's disease

Yang, 2020, Current and projected future economic burden of Parkinson's disease in the U.S, NPJ Parkin. Dis., 6, 15, 10.1038/s41531-020-0117-1 Cacabelos, 2017, Parkinson's disease: from pathogenesis to pharmacogenomics, Int J Mol Sci, 18, 551, 10.3390/ijms18030551 Dennis Dickson, 2018, Neuropathology of Parkinson disease, Park Relat Disord, 46, S30, 10.1016/j.parkreldis.2017.07.033 Rochlani, 2017, Metabolic syndrome: pathophysiology, management, and modulation by natural compounds, Therapeut. Adv. Cardiovas. Dis., 11, 215, 10.1177/1753944717711379 Brown, 2016, Genetics of insulin resistance and the metabolic syndrome, Curr Cardiol Rep, 18, 75, 10.1007/s11886-016-0755-4 Herrero, 2015, Inflammation in Parkinson's disease: role of glucocorticoids, Front Neuroanat, 9, 32, 10.3389/fnana.2015.00032 Nam, 2018, Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study, PLoS Med, 15, 10.1371/journal.pmed.1002640 Leehey, 2017, Association of metabolic syndrome and change in unified Parkinson's disease rating Scale scores, Neurology, 89, 1789, 10.1212/WNL.0000000000004572 2020, Isradipine versus placebo in early Parkinson disease: a randomized trial, Ann Intern Med, 172, 591, 10.7326/M19-2534 Schade, 2020, Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide, Mov Disord, 7, 343, 10.1002/mdc3.12921 Sääksjärvi, 2015, Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease, Park Relat Disord, 21, 1148, 10.1016/j.parkreldis.2015.07.017 Schelp, 2012, Metabolic syndrome and dementia associated with Parkinson's disease: impact of age and hypertension, Arquivos de neuro-psiquiatria, 70, 114, 10.1590/S0004-282X2012000200008